Susan G. Komen San Diego

RACE FOR THE CURE®

In San Diego, six women a day are diagnosed with breast cancer and unfortunately one woman a day passes away from this disease.

Early detection and effective treatment provide the best chance of survival from breast cancer.
And that’s what our work at Susan G. Komen San Diego is all about.

We are the only organization that studies San Diego County to identify the gaps in breast cancer care and the barriers to breast health access. Komen San Diego’s work is about removing barriers, improving the law, changing systems, and most importantly, elevating the women and men directly impacted by breast cancer.

Komen San Diego also has a robust public policy and advocacy arm to assure healthcare access and equity.

Lastly, Susan G. Komen is the largest nonprofit funder of breast cancer research outside of the U.S. government. Much of that investment has been awarded to researchers in San Diego, and nearly 40 percent of our research investment is focused on metastatic disease.

Susan G. Komen® San Diego

RACE FOR THE CURE®

The Walk to End Breast Cancer
Sunday, November 3, 2019

In San Diego, six women a day are diagnosed with breast cancer and unfortunately one woman a day passes away from this disease.

Early detection and effective treatment provide the best chance of survival from breast cancer.
And that’s what our work at Susan G. Komen San Diego is all about.

We are the only organization that studies San Diego County to identify the gaps in breast cancer care and the barriers to breast health access. Komen San Diego’s work is about removing barriers, improving the law, changing systems, and most importantly, elevating the women and men directly impacted by breast cancer.

Komen San Diego also has a robust public policy and advocacy arm to assure healthcare access and equity.

Lastly, Susan G. Komen is the largest nonprofit funder of breast cancer research outside of the U.S. government. Much of that investment has been awarded to researchers in San Diego, and nearly 40 percent of our research investment is focused on metastatic disease.